News

Preliminary research suggests that lopofosine I-131 in combination with external beam radiation is safe and tolerable in patients with relapsed or refractory head and neck cancer.

The FDA has approved ruxolitinib for the treatment of chronic graft-versus-host disease after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older.

The FDA has granted fast track designation to the HER2-targeted chimeric antigen receptor-macrophage, CT-0508, for the treatment of patients with solid tumors.

A biologics license application has been submitted to the FDA for betibeglogene autoemcel gene therapy for the treatment of adult, adolescent, and pediatric patients with B-thalassemia who require regular blood cell transfusions.

American Oncology Network, LLC and Sarah Cannon Research Institute announced today the addition of American Oncology Network partner practice Genesis Cancer and Blood Institute.

Tisotumab vedotin has become the first and only approved antibody-drug conjugate for the treatment of recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.

In an interview with Targeted Oncology™ during the SOHO Annual Meeting, Carole Miller, MD, discussed results from the REVEAL study and how the findings can be used to aid future research.

In an interview with Dana Chase, MD during the ESMO Congress 2021, Chase discussed unmet needs for frontline advanced ovarian cancer treatment and the retrospective analysis of cumulative risk factors and their potential impact on outcome in these patients.

The FDA has approved cabozantinib for the treatment of patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer that has progressed following prior vascular endothelial growth factor receptor-targeted therapy and who are radioactive iodine-refractory or ineligible.

For the treatment of de novo metastatic castration-sensitive prostate cancer improved radiographic progression-free survival and overall survival was seen with the addition of prednisone to androgen-deprivation therapy plus docetaxel.

In a presentation at the 2021 ESMO Congress, researchers discussed how nivolumab plus ipilimumab showed superior efficacy results after a 5-year follow-up in comparison to single-agent sunitinib.

While they may differ by other genetic alterations, patients with VHL mutated clear cell renal cell carcinoma or VHL wild type ccRCC may have similar characteristics.

Outcomes for patients with mantle cell lymphoma are poor after ibrutinib fails, pointing to a need for the development of safe and effective targeted therapies.

Michael D. Chuong, MD, a radiation oncologist and medical director of Proton Therapy at Miami Cancer Institute, Baptist Health South Florida, discusses the benefits of MRI-guided radiation therapy in pancreatic cancer.

Complete surgical removal of a pancreatic tumor is not possible for most patients. Chemotherapy and radiation therapy are typically recommended to slow tumor growth, but ultimately are not expected to be curative, writes Michael Chuong, MD.

Retrospective research suggests a survival benefit with frontline Sequential crizotinib followed by alectinib in ALK-positive non–small cell lung cancer.

The FDA has granted approval to mobocertinib for the treatment of adult patients with locally advanced or metastatic EGFR exon 20 insertion–mutant metastatic non–small cell lung cancer, as detected by an FDA-approved test, and who have received prior platinum-based chemotherapy.

John Diaz, MD, discusses the current results of the phase 1 trial of STRO-002, a novel FRα-targeting antibody-drug conjugate, in patients with ovarian cancer.

An accelerated approval has been granted by the FDA to zanubrutinib, for the treatment of marginal zone lymphoma in patients who have received 1 prior anti-CD20-based therapy.

Durable responses in patients with low-grade upper tract urothelial carcinoma were seen with the mitomycin- containing reverse thermal gel UGN-101.

The current standard of care for BCC is surgical excision. However, the procedure is often time consuming, expensive, and may lead to cosmetic and functional morbidity.

The FDA has accepted the biologics license application for tislelizumab, an anti-PD-1 immune checkpoint inhibitor for the treatment of unresectable recurrent locally advanced or metastatic esophageal squamous cell carcinoma in previously treated patients.

Findings from the S1619 trial signal that a neoadjuvant triplet is safe and effective for the treatment of resectable mesothelioma.

Enrollment has been completed in the VERSATILE-002 trial, a phase 2 study of PDS0101 for the treatment of advanced human papillomavirus-associated head and neck cancer that has returned or spread.

Rapid responses and tolerable safety was shown with minimal residual disease–based consolidation therapy with daratumumab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma.

Roughly 50% of patients with clear cell renal cell carcinoma responded to the combination of nivolumab plus ipilimumab in a Japanese study, and varied responses occurred in those with nonclear cell histology.

Compared to those who are overweight or of a normal weight, patients who are obese are more likely to have better disease-specific and overall survival in metastatic castration-resistant prostate cancer.

In an interview with Targeted Oncology, John Diaz, MD, discussed the ovarian cancer treatment paradigm and the promise of STRO-002 for an important ovarian cancer subgroup.

The FDA has granted a breakthrough device designation to the NovoTTF-200T System, a tumor treating fields delivery system, for the treatment of unresectable or metastatic liver cancer.

Results from a phase 1/2 study showed a high rate of objective response with mobocertinib in a subset of patients with EGFR exon 20 insertion mutation–positive non–small cell lung cancer.